Blood-based, non-invasive analytics that quantify target expression, track circulating tumor cells, and validate biomarkers — backed by immunoassay, biosensor, NGS genotyping, and single-cell long-read sequencing platforms to guide patient selection and pharmacodynamic monitoring across antibody-drug conjugate (ADC) programs.
Antibody-drug conjugates are among the fastest-growing modalities in oncology, yet their development is frequently slowed by one practical question: is the target there, and is it still there during treatment? Serial tissue biopsies are invasive, often impractical, and capture only a single lesion at a single time point.
Alfa Oncology's liquid biopsy service line addresses this gap with circulating tumor cell (CTC) and cell-free analyte assays that quantify ADC targets such as TROP2 and HER2, profile heterogeneity, and deliver longitudinal pharmacodynamic readouts. Around this core, we operate a complete bioanalytical stack — photoelectrochemical immunoassays, electrochemical biosensors, heterojunction-based assay optimization, NGS genotyping, and single-cell long-read sequencing — so that target biology, assay chemistry, and genomic readouts are developed under one program rather than stitched together across vendors.
Every project runs through documented assay validation, QC checkpoints, and interpretive reporting — supporting go/no-go decisions from candidate selection through clinical monitoring.
Each module stands alone or combines into a complete monitoring package for your ADC or targeted therapy program — from circulating analyte detection through genomic and single-cell readouts.
Quantify target antigen expression (e.g., TROP2, HER2) on circulating tumor cells to define responder populations and monitor target modulation during therapy — validated assays for breast cancer and beyond.
Learn More →Non-invasive CTC capture, enumeration, molecular profiling, and longitudinal monitoring of tumor burden, heterogeneity, and treatment response — without repeated tissue biopsies.
Learn More →End-to-end biomarker assay development — from discovery through analytical and clinical validation — using ctDNA, CTCs, and exosomes to predict PK/PD, efficacy, and resistance mechanisms for ADC therapies.
Learn More →Photoelectrochemical (PEC) immunoassay development for ultrasensitive detection of low-abundance biomarkers — heterostructure signal amplification with custom antibody pairing and matrix compatibility testing.
Learn More →Biosensor development and validation from concept to qualified platform — electrode design, surface chemistry, analytical validation for sensitivity, specificity, and reproducibility in complex biological matrices.
Learn More →Targeted panels through whole-exome workflows for SNVs, indels, and copy number alterations — with documented QC metrics, annotated variant calling, and interpretive reports linking genotype to phenotype.
Learn More →Experimental design, sequencing, and validated pipelines for high-throughput screens — read counting, statistical analysis, and pathway-level interpretation delivered as analysis-ready reports.
Learn More →Custom bioinformatics for single-cell long-read transcriptomics — full-length isoform reconstruction, splicing dynamics, and cell-level transcript diversity beyond short-read resolution.
Learn More →Systematic optimization of heterojunction materials for assay performance — interfacial engineering and heat-treatment strategies that raise signal intensity, stability, and limit of detection.
Learn More →Define the program question — target, indication, sample matrix, and longitudinal schedule.
Assay selection or custom development, with analytical validation against your acceptance criteria.
CTC enrichment, target expression detection, immunoassay or biosensor measurement, and sequencing on your study samples.
Analysis-ready reports with longitudinal trending and bioinformatic interpretation to support go/no-go and monitoring decisions.
Liquid biopsy readouts link directly to our preclinical and disease model resources across major indications.
Deep expertise spanning antigen biology, ADC mechanisms, and circulating biomarker analytics.
Validated platforms for CTC enrichment, PEC immunoassay, electrochemical biosensing, multiplex target detection, and short- and long-read sequencing.
Assay panels, sequencing depth, and sampling schedules tailored to your target, indication, and development stage.
Documented validation, QC checkpoints at every processing step, and reliable, interpretation-ready data support.
Selected peer-reviewed publications underpinning the methodologies behind our liquid biopsy and bioanalytical platforms.
Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells
View article →Liquid biopsy in cancer: current status, challenges and future prospects (Ma et al., 2024)
View article →Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications (Dai et al., 2025)
View article →Yes. Our ADC Drug Target Expression Analysis Services service is designed to detect and quantify target antigens such as TROP2 and HER2 on CTCs, enabling patient stratification and treatment-phase target monitoring from a simple blood draw.
Schedules are customizable. Typical pharmacodynamic monitoring designs use baseline plus 2–4 on-treatment time points; our team will help define a sampling plan that matches your dosing cycle and decision points.
Yes. While TROP2- and HER2-targeted programs are our most requested workflows, biomarker development is target-agnostic and can be built around your ADC's antigen, payload resistance genes, or pathway markers using ctDNA, CTC, or exosome analytes.
Yes. NGS genotyping, high-throughput sequencing with bioinformatics, and single-cell long-read analysis can be run alongside CTC and biomarker assays, so target-level and genome-level evidence are delivered in one integrated report.
Biomarker and CTC readouts integrate naturally with our preclinical services — for example, pairing pharmacodynamic monitoring with efficacy testing or ADME/PK studies to build a complete translational package.
Tell us about your target and indication — our scientists will propose a monitoring design within 1–2 business days.